---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269533"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:38:26.712915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones

## Summary
- Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.
- R&D expenses $15.3M (-$6.1M YoY); G&A $6.4M (-$1.5M YoY); total operating expense $21.7M.
- CX-2051 Phase 1 enrollment ~100 patients by Q1 2026 data update; Phase 1b combo with bevacizumab starts Q1 2026.
- CX-801 Phase 1 monotherapy biomarker data at SITC 2025; combo with KEYTRUDA dose escalation enrolling 2nd dose level.
- Appointed Rachael Lester as SVP, Chief Business Officer in October 2025.

## SEC filing metadata
- accession: 0001193125-25-269533
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312525269533/0001193125-25-269533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312525269533/ctmx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269533
- JSON: https://secwatch.observer/filing/0001193125-25-269533.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.